ID   HCC827 PFR5
AC   CVCL_DH95
SY   HCC827 PFR-5
DR   cancercelllines; CVCL_DH95
DR   GEO; GSM466329
DR   Progenetix; CVCL_DH95
DR   Wikidata; Q54881798
RX   PubMed=20129249;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:132268; Dacomitinib (PF-00299804).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2063 ! HCC827
SX   Female
AG   39Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 12
//
RX   PubMed=20129249; DOI=10.1016/j.ccr.2009.11.022;
RA   Schrock A.B., Zejnullahu K., Wu Y.-L., Song Y., Dias-Santagata D.,
RA   Lifshits E., Toschi L., Rogers A., Mok T., Sequist L.V., Lindeman N.I.,
RA   Murphy C., Akhavanfard S., Yeap B.Y., Xiao Y., Capelletti M.,
RA   Iafrate A.J., Lee C., Christensen J.G., Engelman J.A., Janne P.A.;
RT   "Preexistence and clonal selection of MET amplification in EGFR mutant
RT   NSCLC.";
RL   Cancer Cell 17:77-88(2010).
//